Neurega-150
Capsules
Dose Type
Information
Neurega-150 contains Pregabalin 150 mg as acitve ingredient. Pregabalin works by slowing down impulses in the brain that cause seizures. It also affects chemicals in the brain that send pain signals across the nervous system. It is used to control seizures and to treat fibromyalgia. It is also used to treat pain caused by nerve damage in people with diabetes (diabetic neuropathy), herpes zoster (post-herpetic neuralgia, or neuropathic pain associated with spinal cord injury.
Therapeutic Class
Anticonvulsant/Anti-epileptic
Dose and Direction of Use
For oral administration and can be taken with or without food. Follow the dose and duration as prescribed by the doctor.
Discontinuation of Pregabalin: In accordance with current clinical practice, if Pregabalin has to be discontinued, it is recommended this should be done gradually over a minimum of 1 week independent of the indication.
Mode of Action
Pregabalin binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. Thus, Pregabalin decreases the pain by modulating calcium channel activity of the nerve cells.
Uses
- Neuropathic pain: Pregabalin is indicated for the treatment of peripheral and central neuropathic pain in adults.
- Epilepsy: Pregabalin is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.
- Generalised anxiety disorder:Pregabalin is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.
Contraindications
Don't use this medicine if you have:
- Hypersensitivity to pregabalin
Precautions and Warning
- Consult with your doctor if you are pregnant or breast feeding woman before taking this medicine to understand the risk and benefit ratio.
- Talk to your doctor about past medical history like kidney problem or liver problem before taking this medicine
- Don't double the dose for the missed one.
- Complete the prescribed dose and duration of medicine.
- Some diabetic patients who gain weight on Pregabalin treatment may need to adjust hypoglycemic medications.
- Visual adverse reactions have also been reported, including loss of vision, visual blurring or other changes of visual acuity, many of which were transient. Discontinuation of Pregabalin may result in resolution or improvement of these visual symptoms.
- Convulsions, including status epilepticus and grand mal convulsions, may occur during Pregabalin use or shortly after discontinuing Pregabalin.
- Congestive heart failure in some patients receiving Pregabalin has been reported, mostly in elderly cardiovascular compromised patients during treatment for a neuropathic indication. Discontinuation of Pregabalin may resolve the reaction.
- Patients with a history of substance abuse should be monitored for symptoms of Pregabalin abuse.
- Cases of encephalopathy have been reported, mostly in patients with underlying conditions that may precipitate encephalopathy.
- Pregabalin treatment has been associated with dizziness and somnolence, which could increase the occurrence of accidental injury in elderly population. Cases of loss of consciousness, confusion and mental impairment have also been reported. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medication.
- After discontinuation of short-term and long-term treatment with Pregabalin withdrawal symptoms have been observed in some patients, (e.g. insomnia, headache, nausea, diarrhoea, flu syndrome, nervousness, depression, pain, sweating and dizziness). The patient should be informed about this at the start of the treatment. Concerning discontinuation of long-term treatment of Pregabalin, data suggest that the incidence and severity of withdrawal symptoms may be dose related.
- In the treatment of central neuropathic pain due to spinal cord injury the incidence of adverse events in general, central nervous system adverse events and especially somnolence was increased. This may be attributed to an additive effect due to concomitant medication (e.g. anti-spasticity agents) needed for this condition.
- Cases of renal failure have been reported. Some cases were reversible upon discontinuation of treatment.
- Patients should be monitored for signs of suicidal ideation and behaviors. Appropriate treatment should be considered.
- When Pregabalin and opioids are co-administered, measures to prevent constipation may be considered (especially in female patients and elderly).
